Century Therapeutics Inc. (IPSC)
The price, the headline numbers and the latest news, in one place.
Century Therapeutics Inc. (IPSC) Stock Price, Analysis & Data
| Bid | 1.5 |
| Market Cap | 374.83M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -109.79M |
| 1.60 | |
| -0.95 | |
| n/a | |
| -4.57 | |
| P/B (ttm) | 1.61 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 12, 2026 |
| Ask | 2.62 |
| Volume | 326,038 |
| Avg. Volume (20D) | 1,218,256 |
| Open | 2.05 |
| Previous Close | 2.02 |
| Day's Range | 2.02 - 2.08 |
| 52-Week Range | 0.43 - 3.04 |
| Analyst | Buy |
| Price Target | 4.5 (117.39%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About IPSC
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-...
Financial Performance
In 2025, Century Therapeutics's revenue was 109.16M, an increase of 1,556.76% compared to the previous year's 6.59M. Earnings were -9.58M, a decrease of -92.43%.
Financial StatementsAnalyst Forecast
According to 4 analyst ratings, the average rating for IPSC stock is "Buy". The 12-month stock price forecast is 4.5, which is upside of 117.39% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $0 misses estimates by $0, with -100.00% YoY decline.
- EPS of -0.11 exceeds estimates by 0.01, with 71.05% YoY growth.
Analysts project revenue of ... Upgrade
